Monday, October 7, 2019

Jouranl 3 - Probiotics and Sickness Behavior


This week’s article looked at the relationship between sickness behavior and the gut biome and more specifically the influence of probiotics. I found the article as a whole quite interesting, as the gut-brain connection is largely novel to me, the introduction two weeks ago was my first time learning about it. I found it interesting that the introduction focused more on the previous studies/knowledge on which several of the paper’s claims were based, instead of talking about the relevance and implications of the research. ‘
As with previous studies, it is noteworthy that this one used only male mice. And also, as with previous studies, I would question how well social exploratory behavior is indicative of sickness behavior specifically. The article states that it is a “highly reproducible and robust behavioral paradigm,” however the paradigm was also used to measure depression, so that raises some questions. I am a little confused as to why gut permeability was measured, and because there was no significant difference between the mice it was not really further discussed.
Within the results for the sickness behavior it was interesting that both the time spent in social investigation and time spend being immobile were included. While the difference in social investigation between BDL placebo mica and BDL VS3 mice was statistically significant it appears that the difference is much smaller than comparing the sham surgery to the BDL surgery in general. The difference in time spent immobile seems to be much larger. I do wonder how different the sham surgery is from the BDL surgery and where these behavioral differences are due to inflammation induced sickness behavior or due to other surgical complications.
The most confusing result for me was the composition of the gut microbiota between the surgery groups and between the VSL#3 treatment groups was not different. While the changes in behavior and effects on systemic immunity seem to be clearly linked to the surgery or to the VSL#3 treatment, I would have thought this would be reflected in a different microbiome composition. On the other hand, the clearest and seemingly relevant result is the difference in TNF-alpha levels between BDL placebo and BDL VSL#3 mice. This was then linked to the novel pathway that the increased microglial activation is followed by monocyte recruitment int the brain which leads to the development of sickness behaviors.
The discussion cited a study about long term hippocampal potentiation in a diabetes model due to probiotic, which is very interesting to me. I think I will write my grant proposal about something diabetes related so I will check out that article.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.